IP
HAE icon

Isthmus Partners’s Haemonetics HAE Stock Holding History

Isthmus Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.68M Sell
65,229
-2,381
-4% -$155K 0.39% 64
2025
Q4 		$5.42M Buy
67,610
+5,908
+10% +$397K 0.6% 47
2025
Q3 		$3.01M Buy
61,702
+16,505
+37% +$1.02M 0.67% 41
2025
Q2 		$3.37M Buy
45,197
+2,732
+6% +$181K 0.39% 71
2025
Q1 		$2.7M Buy
42,465
+2,245
+6% +$153K 0.34% 74
2024
Q4 		$3.14M Buy
40,220
+450
+1% +$36.1K 0.38% 70
2024
Q3 		$3.2M Sell
39,770
-8,326
-17% -$673K 0.38% 68
2024
Q2 		$3.98M Buy
48,096
+58
+0.1% +$5.1K 0.47% 61
2024
Q1 		$4.1M Buy
48,038
+30,150
+169% +$2.37M 0.47% 61
2023
Q4 		$1.53M Buy
+17,888
New +$1.55M 0.2% 102
2016
Q1 		– Sell
-13,300
Closed -$429K – 247
2015
Q4 		$429K Buy
13,300
+1,056
+9% +$34.3K 0.15% 108
2015
Q3 		$396K Buy
12,244
+305
+3% +$11.5K 0.15% 103
2015
Q2 		$494K Buy
11,939
+634
+6% +$26.7K 0.16% 100
2015
Q1 		$508K Buy
11,305
+446
+4% +$18.6K 0.17% 89
2014
Q4 		$406K Buy
+10,859
New +$398K 0.14% 105

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Isthmus Partners's HAE Position: Q1 2026 in Review

Isthmus Partners reduced its Haemonetics (HAE) stake by 3.5% in Q1 2026, selling an estimated $155K and leaving 65,229 shares worth $3.68M. The position accounts for 0.39% of the portfolio, ranked #64.

Isthmus Partners first reported a position in HAE in Q4 2014 and has held it in 15 quarters since. The position peaked at $5.42M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Isthmus Partners held 65,229 shares of Haemonetics worth $3.68M as of Q1 2026.
  • Isthmus Partners sold 2,381 Haemonetics shares in Q1 2026, an estimated $155K.
  • Haemonetics made up 0.39% of Isthmus Partners's portfolio in Q1 2026, its #64 holding.
  • Isthmus Partners first reported a position in Haemonetics in Q4 2014 and has held it in 15 quarters since.
  • Isthmus Partners's Haemonetics position peaked at $5.42M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Isthmus Partners's 13F filing for Q1 2026, filed 30 Apr 2026.